A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (NCT07634471)
A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Who can join: Review the eligibility criteria below.
Location: Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307) — Durham, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307) — Durham, North Carolina
- SCRI Oncology Partners ( Site 7000) — Nashville, Tennessee
- Instituto Alexander Fleming ( Site 0105) — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Sanatorio Nuestra Senora del Rosario ( Site 0104) — Rosario, Santa Fe Province
- Hospital Privado Universitario de Córdoba ( Site 0102) — Córdoba,
- Box Hill Hospital ( Site 0201) — Box Hill, Victoria
- Beijing Cancer hospital ( Site 0501) — Beijing, Beijing Municipality
- Hadassah Medical Center ( Site 0701) — Jerusalem,
- Sheba Medical Center ( Site 0702) — Ramat Gan,
- Sourasky Medical Center ( Site 0704) — Tel Aviv,
- Samsung Medical Center ( Site 0801) — Seoul,
- Institut Català d'Oncologia (ICO) - Badalona ( Site 0904) — Badalona, Barcelona
- Hospital Virgen de la Victoria ( Site 0905) — Málaga, Malaga
- Hospital Universitari Vall de Hebron ( Site 0903) — Barcelona,
- Hospital Universitario Gregorio Maranon ( Site 0902) — Madrid,
- Hospital Universitario de Salamanca ( Site 0906) — Salamanca,
- National Taiwan University Hospital ( Site 1001) — Taipei,
- Chang Gung Medical Foundation-Linkou Branch ( Site 1002) — Taoyuan,
- Hacettepe Universite Hastaneleri ( Site 1110) — Ankara,
- Sisli Florence Nightingale Hastanesi ( Site 1112) — Istanbul,
- Ondokuz Mayıs Universitesi ( Site 1113) — Samsun,
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California
Explore by condition: All Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.